Enzyme News and Research

RSS

Bat and pangolin coronavirus structure sheds light on SARS-CoV-2 evolution

Researchers at Tsinghua University, Beijing, have conducted a study providing possible new insights into the evolution and cross-species transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

23 Sep 2020

Owlstone Medical releases positive study results on use of breath biopsy for better liver disease diagnosis

Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, today announced the results of a patient study that successfully demonstrates the use of exhaled limonene as a breath biomarker to measure liver function and stage liver disease.

From Owlstone Medical Ltd 23 Sep 2020

Molecular dynamic simulations reveal detailed spike-ACE2 interactions

The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.

23 Sep 2020

Common genetic variants may influence susceptibility to COVID-19

Researchers in the United States and Japan have conducted a study suggesting that a commonly occurring genetic variant influences susceptibility to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

23 Sep 2020

Acquisition of a natural mutation primes SARS-CoV-2 for neutralization by a cross-reactive antibody

A team of scientists from the United States reveals that the acquisition of a natural mutation makes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptible to neutralization by a cross-reactive SARS-CoV antibody. The study is currently available on the bioRxiv* preprint server.

22 Sep 2020

Nanoparticle SARS-CoV-2 model could potentially speed the search for drugs

A team of scientists from the National Center for Advancing Translational Sciences and Naval Research Laboratory in Washington, D.C., has developed a new tool that mimics how SARS-CoV-2 -- the virus that causes COVID-19 -- infects a cell, information that could potentially speed the search for treatments against the disease.

22 Sep 2020

A cost-effective scalable production of SARS-CoV-2 RBD in yeast

A new study by the Argentinian AntiCovid Consortium and published in the preprint server bioRxiv* in September 2020 reports on the successful characterization of the conformation and stability of the SARS-CoV-2 spike protein receptor-binding domain (RBD) in two different cell systems. This may help to accelerate the development of vaccines and neutralizing antibodies.

21 Sep 2020

Soluble ACE2 microbody blocks SARS-CoV-2 entry into lung cells

A new study by researchers at NYU Langone Medical Center and Weill Cornell Medical College and published on the preprint server bioRxiv* in September 2020 reports the potential of an angiotensin-converting enzyme 2 (ACE2)-antibody Fc complex in a new format that seems to offer more significant inhibition of SARS-CoV-2.

21 Sep 2020

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

A recent study published on the preprint server bioRxiv* in September 2020 shows the value of drug combinations to enhance the therapeutic and preventive efficacy of such repositioned drugs in standard antiviral therapy.

20 Sep 2020

Lopinavir-ritonavir does not suppress SARS-CoV-2 activity in vitro

Among them is the combination of lopinavir and ritonavir, which have been in use in an attempt to reduce the severity of the disease. However, a new South Korean study published on the preprint server bioRxiv in September 2020 shows that this combination is ineffective against the virus.

20 Sep 2020

Large mother-child paired study promises more answers on COVID-19 in pregnancy

A new paper published in the preprint server medRxiv* in August 2020 reports the design and preliminary findings of an ongoing study on pregnant mothers and their children born during the pandemic.

20 Sep 2020

Adaptations found in RNA secondary structure in genes of two proteins of SARS-CoV-2

To investigate mutations in coronaviruses, a new study by scientists at Duke University and published on the preprint server bioRxiv, used a computational methodology, adaptiPhy, which identifies extra nucleotide substitutions in certain parts of the viral genome compared to mutations that have no effect on the genome.

18 Sep 2020

Researchers identify new path to defeating chronic myelogenous leukemia

Researchers have identified a second path to defeating chronic myelogenous leukemia, which tends to affect older adults, even in the face of resistance to existing drugs.

18 Sep 2020

Researchers develop non-infectious nanoparticle probes to study SARS-CoV-2

Scientists and researchers at the U.S. Naval Research Laboratory and National Center for Advancing Translational Sciences, submitted their findings to ACS Nano, a monthly peer-reviewed scientific journal, on their collaboration to develop SARS-CoV-2 nanoparticle probes that are used to study fundamental interactions between SARS-CoV-2 Spike proteins and human cells.

18 Sep 2020

S-pseudotyped VLPs offer promising COVID-19 vaccine platform

A new study published on the preprint server bioRxiv* in September 2020 reports on a Moloney murine leukemia virus (MLV) platform that produces VLPs expressing the important spike antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Sep 2020

Key China COVID-19 study produced results that influenced subsequent research on coronavirus

Early in the onset of the COVID-19 pandemic, a small study in China produced results that influenced subsequent research on the virus.

18 Sep 2020

Study invalidates Ebselen and other broad-spectrum SARS-CoV-2 Mpro inhibitors

Other novel compounds with Mpro inhibitory activity have also been claimed to have antiviral activity. These include ebselen, disulfiram, tideglusib, carmofur, shikonin, and PX-12. A new research paper discusses the role of these molecules as potential Mpro inhibitors in the prevention of SARS-CoV-2 infection.

18 Sep 2020